KR102440573B1 - Composition for Prebiotics Containing Poly-Gamma-Glutamate - Google Patents
Composition for Prebiotics Containing Poly-Gamma-Glutamate Download PDFInfo
- Publication number
- KR102440573B1 KR102440573B1 KR1020160146854A KR20160146854A KR102440573B1 KR 102440573 B1 KR102440573 B1 KR 102440573B1 KR 1020160146854 A KR1020160146854 A KR 1020160146854A KR 20160146854 A KR20160146854 A KR 20160146854A KR 102440573 B1 KR102440573 B1 KR 102440573B1
- Authority
- KR
- South Korea
- Prior art keywords
- glutamic acid
- present
- polygamma
- gamma
- acid
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 30
- 235000013406 prebiotics Nutrition 0.000 title claims abstract description 30
- 239000004220 glutamic acid Substances 0.000 claims abstract description 40
- 230000036541 health Effects 0.000 claims description 12
- 150000003839 salts Chemical class 0.000 claims description 12
- 235000013305 food Nutrition 0.000 claims description 11
- 235000013376 functional food Nutrition 0.000 claims description 6
- 239000004480 active ingredient Substances 0.000 claims description 5
- 241001468155 Lactobacillaceae Species 0.000 claims description 3
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical group [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 claims description 3
- 241001112695 Clostridiales Species 0.000 claims description 2
- 230000007423 decrease Effects 0.000 claims 1
- 230000000968 intestinal effect Effects 0.000 abstract description 19
- 241000894006 Bacteria Species 0.000 abstract description 18
- 230000009286 beneficial effect Effects 0.000 abstract description 9
- 230000000694 effects Effects 0.000 abstract description 5
- 230000002401 inhibitory effect Effects 0.000 abstract description 5
- 230000001737 promoting effect Effects 0.000 abstract description 4
- 229960002989 glutamic acid Drugs 0.000 description 38
- -1 for example Chemical class 0.000 description 14
- 239000008194 pharmaceutical composition Substances 0.000 description 13
- 239000002253 acid Substances 0.000 description 11
- 239000000243 solution Substances 0.000 description 10
- 235000013361 beverage Nutrition 0.000 description 9
- 239000000725 suspension Substances 0.000 description 9
- 239000000796 flavoring agent Substances 0.000 description 8
- 235000013355 food flavoring agent Nutrition 0.000 description 7
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 6
- 230000037406 food intake Effects 0.000 description 6
- 210000001035 gastrointestinal tract Anatomy 0.000 description 6
- 210000000056 organ Anatomy 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- 239000000969 carrier Substances 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 210000002429 large intestine Anatomy 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 235000014633 carbohydrates Nutrition 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 239000000284 extract Substances 0.000 description 4
- 210000003608 fece Anatomy 0.000 description 4
- 210000000936 intestine Anatomy 0.000 description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 229920001542 oligosaccharide Polymers 0.000 description 4
- 150000002482 oligosaccharides Chemical class 0.000 description 4
- 210000000813 small intestine Anatomy 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 3
- 244000063299 Bacillus subtilis Species 0.000 description 3
- 235000014469 Bacillus subtilis Nutrition 0.000 description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 235000010443 alginic acid Nutrition 0.000 description 3
- 239000000783 alginic acid Substances 0.000 description 3
- 229920000615 alginic acid Polymers 0.000 description 3
- 229960001126 alginic acid Drugs 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 235000014113 dietary fatty acids Nutrition 0.000 description 3
- 239000000194 fatty acid Substances 0.000 description 3
- 229930195729 fatty acid Natural products 0.000 description 3
- 238000000855 fermentation Methods 0.000 description 3
- 230000004151 fermentation Effects 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 239000000600 sorbitol Substances 0.000 description 3
- 235000010356 sorbitol Nutrition 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 238000007920 subcutaneous administration Methods 0.000 description 3
- 235000000346 sugar Nutrition 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 230000000699 topical effect Effects 0.000 description 3
- 210000002700 urine Anatomy 0.000 description 3
- 235000013343 vitamin Nutrition 0.000 description 3
- 239000011782 vitamin Substances 0.000 description 3
- 229940088594 vitamin Drugs 0.000 description 3
- 229930003231 vitamin Natural products 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- 241000193830 Bacillus <bacterium> Species 0.000 description 2
- 206010010774 Constipation Diseases 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 241000186660 Lactobacillus Species 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 244000299461 Theobroma cacao Species 0.000 description 2
- 150000004781 alginic acids Chemical class 0.000 description 2
- 229940024606 amino acid Drugs 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 239000007900 aqueous suspension Substances 0.000 description 2
- 235000019445 benzyl alcohol Nutrition 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 235000019219 chocolate Nutrition 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 108010083364 chungkookjang Proteins 0.000 description 2
- 210000001072 colon Anatomy 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 239000002270 dispersing agent Substances 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 239000008298 dragée Substances 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 230000002550 fecal effect Effects 0.000 description 2
- 235000015203 fruit juice Nutrition 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 235000013922 glutamic acid Nutrition 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 235000020256 human milk Nutrition 0.000 description 2
- 210000004251 human milk Anatomy 0.000 description 2
- 238000001095 inductively coupled plasma mass spectrometry Methods 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000007913 intrathecal administration Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 239000004310 lactic acid Substances 0.000 description 2
- 235000014655 lactic acid Nutrition 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 230000000813 microbial effect Effects 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 239000002480 mineral oil Substances 0.000 description 2
- 235000010446 mineral oil Nutrition 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 239000000346 nonvolatile oil Substances 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 238000012175 pyrosequencing Methods 0.000 description 2
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 239000012488 sample solution Substances 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- 150000003722 vitamin derivatives Chemical class 0.000 description 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- 108020004465 16S ribosomal RNA Proteins 0.000 description 1
- LEACJMVNYZDSKR-UHFFFAOYSA-N 2-octyldodecan-1-ol Chemical compound CCCCCCCCCCC(CO)CCCCCCCC LEACJMVNYZDSKR-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 241000194110 Bacillus sp. (in: Bacteria) Species 0.000 description 1
- 238000011740 C57BL/6 mouse Methods 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000792859 Enema Species 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- 239000001512 FEMA 4601 Substances 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 239000004378 Glycyrrhizin Substances 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 239000012981 Hank's balanced salt solution Substances 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- 239000005909 Kieselgur Substances 0.000 description 1
- 150000008539 L-glutamic acids Chemical class 0.000 description 1
- 241000186712 Lactobacillus animalis Species 0.000 description 1
- 241001640457 Lactobacillus intestinalis Species 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- HELXLJCILKEWJH-SEAGSNCFSA-N Rebaudioside A Natural products O=C(O[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@@]1(C)[C@@H]2[C@](C)([C@H]3[C@@]4(CC(=C)[C@@](O[C@H]5[C@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@H](O)[C@@H](CO)O5)(C4)CC3)CC2)CCC1 HELXLJCILKEWJH-SEAGSNCFSA-N 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 244000098338 Triticum aestivum Species 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 235000014171 carbonated beverage Nutrition 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229940081733 cetearyl alcohol Drugs 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000013325 dietary fiber Nutrition 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- AIUDWMLXCFRVDR-UHFFFAOYSA-N dimethyl 2-(3-ethyl-3-methylpentyl)propanedioate Chemical compound CCC(C)(CC)CCC(C(=O)OC)C(=O)OC AIUDWMLXCFRVDR-UHFFFAOYSA-N 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000013583 drug formulation Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 239000008387 emulsifying waxe Substances 0.000 description 1
- 239000007920 enema Substances 0.000 description 1
- 229940095399 enema Drugs 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- HELXLJCILKEWJH-UHFFFAOYSA-N entered according to Sigma 01432 Natural products C1CC2C3(C)CCCC(C)(C(=O)OC4C(C(O)C(O)C(CO)O4)O)C3CCC2(C2)CC(=C)C21OC(C1OC2C(C(O)C(O)C(CO)O2)O)OC(CO)C(O)C1OC1OC(CO)C(O)C(O)C1O HELXLJCILKEWJH-UHFFFAOYSA-N 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- MEANOSLIBWSCIT-UHFFFAOYSA-K gadolinium trichloride Chemical compound Cl[Gd](Cl)Cl MEANOSLIBWSCIT-UHFFFAOYSA-K 0.000 description 1
- 208000021302 gastroesophageal reflux disease Diseases 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000005182 global health Effects 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- UBHWBODXJBSFLH-UHFFFAOYSA-N hexadecan-1-ol;octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO.CCCCCCCCCCCCCCCCCCO UBHWBODXJBSFLH-UHFFFAOYSA-N 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 201000009863 inflammatory diarrhea Diseases 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 229940102223 injectable solution Drugs 0.000 description 1
- 229940102213 injectable suspension Drugs 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 208000002551 irritable bowel syndrome Diseases 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 229940039696 lactobacillus Drugs 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 229940042472 mineral oil Drugs 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000000663 muscle cell Anatomy 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 231100000344 non-irritating Toxicity 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000007935 oral tablet Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- LCLHHZYHLXDRQG-ZNKJPWOQSA-N pectic acid Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)O[C@H](C(O)=O)[C@@H]1OC1[C@H](O)[C@@H](O)[C@@H](OC2[C@@H]([C@@H](O)[C@@H](O)[C@H](O2)C(O)=O)O)[C@@H](C(O)=O)O1 LCLHHZYHLXDRQG-ZNKJPWOQSA-N 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000010318 polygalacturonic acid Substances 0.000 description 1
- 239000002861 polymer material Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 1
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Chemical class 0.000 description 1
- 229940113124 polysorbate 60 Drugs 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 235000012015 potatoes Nutrition 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 239000006041 probiotic Substances 0.000 description 1
- 235000018291 probiotics Nutrition 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 235000019203 rebaudioside A Nutrition 0.000 description 1
- 229940100618 rectal suppository Drugs 0.000 description 1
- 239000006215 rectal suppository Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 238000011218 seed culture Methods 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000012439 solid excipient Substances 0.000 description 1
- 230000003381 solubilizing effect Effects 0.000 description 1
- 239000001587 sorbitan monostearate Substances 0.000 description 1
- 235000011076 sorbitan monostearate Nutrition 0.000 description 1
- 229940035048 sorbitan monostearate Drugs 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000003871 white petrolatum Substances 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/175—Amino acids
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K10/00—Animal feeding-stuffs
- A23K10/10—Animal feeding-stuffs obtained by microbiological or biochemical processes
- A23K10/16—Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions
- A23K10/18—Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions of live microorganisms
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/142—Amino acids; Derivatives thereof
- A23K20/147—Polymeric derivatives, e.g. peptides or proteins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/765—Polymers containing oxygen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/32—Foods, ingredients or supplements having a functional effect on health having an effect on the health of the digestive tract
- A23V2200/3204—Probiotics, living bacteria to be ingested for action in the digestive tract
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/02—Acid
- A23V2250/06—Amino acid
- A23V2250/0618—Glutamic acid
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Polymers & Plastics (AREA)
- Microbiology (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Food Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Veterinary Medicine (AREA)
- Animal Husbandry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Nutrition Science (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
본 발명은 폴리감마글루탐산을 함유하는 프리바이오틱스 조성물에 관한 것으로, 본 발명에 따른 폴리감마글루탐산을 함유하는 조성물은 장내 유익균의 증식을 촉진시키고 장내 유해균의 생육을 억제할 수 있는 효과가 있다.The present invention relates to a prebiotic composition containing poly-gamma-glutamic acid, and the composition containing poly-gamma-glutamic acid according to the present invention has the effect of promoting the growth of beneficial intestinal bacteria and inhibiting the growth of harmful intestinal bacteria.
Description
본 발명은 폴리감마글루탐산을 함유하는 프리바이오틱스 조성물에 관한 것으로 더욱 자세하게는 장내 유익균의 증식을 촉진시키고 장내 유해균의 생육을 억제할 수 있는 폴리감마글루탐산을 함유하는 프리바이오틱스 조성물에 관한 것이다.The present invention relates to a prebiotic composition containing poly-gamma-glutamic acid, and more particularly, to a prebiotic composition containing poly-gamma-glutamic acid capable of promoting the growth of beneficial intestinal bacteria and inhibiting the growth of harmful intestinal bacteria.
장내 미생물도 우리가 섭취하는 식품을 이용하여 성장하므로 섭취하는 음식물이 장에 존재하는 미생물의 종류를 변화시킬 수 있다. 그 중에서도 식이섬유, 올리고당, 흡수되지 않은 당류 등이 장내 미생물의 성장에 영향을 준다. 이와 같이 인체에 유익한 장내 미생물의 성장을 도와주는 성분이 프리바이오틱스이다. 프리바이오틱스는 소장에서 소화가 되지 않으며, 대장으로 이동하여 유산균과 같은 박테리아의 성장이나 활성을 선택적으로 높여 인체의 건강을 증진시킨다.Intestinal microbes also grow using the foods we eat, so the foods we eat can change the types of microbes in the gut. Among them, dietary fiber, oligosaccharides, and unabsorbed sugars affect the growth of intestinal microbes. Prebiotics are ingredients that help the growth of beneficial intestinal microbes in the human body. Prebiotics are not digested in the small intestine and move to the large intestine to selectively increase the growth or activity of bacteria such as lactic acid bacteria, thereby improving human health.
프리바이오틱스는 올리고당이 인체의 장에 존재하는 유산균을 선택적으로 증가시킨다는 것이 알려지면서부터 언급되기 시작했다. 올리고당은 대장에서 유산균을 선택적으로 성장시키고 장내 유해균의 성장은 막아주는 작용을 한다. 모유를 먹고 자란 아이들이 면역력이 뛰어난 이유가 바로 모유 속의 올리고당 덕분이다. 유산균은 식품발효에 관여하면서 장내 염증성 질병, 설사, 변비 등을 예방하며, 혈액 내 콜레스테롤을 감소시키고, 장내 유해균의 성장을 억제하는 등 우리 몸에 유익한 작용을 한다. 그러므로 프리바이오틱스를 섭취해 유산균의 성장을 증진시키는 것은 장 건강뿐만 아니라 전체적인 건강을 유지하는 방법이 될 수 있다. Prebiotics began to be mentioned when it became known that oligosaccharides selectively increase lactobacilli present in the human gut. Oligosaccharides selectively grow lactic acid bacteria in the large intestine and prevent the growth of harmful bacteria in the intestine. The reason children who grew up on breast milk have excellent immunity is thanks to the oligosaccharides in breast milk. Lactobacillus is involved in food fermentation and has beneficial effects on our body, such as preventing intestinal inflammatory diseases, diarrhea, and constipation, reducing cholesterol in the blood, and inhibiting the growth of harmful bacteria in the intestine. Therefore, taking prebiotics to promote the growth of probiotics can be a way to maintain overall health as well as gut health.
글로벌 프리바이오틱스 시장은 지난해 33억1천만불 규모를 형성한 데 이어 '16∼'23년 기간 동안 연평균 11.6%의 성장세를 지속할 수 있을 전망이다(글로벌 보건산업동향, 보건산업진흥원). 이 같은 성장세는 당뇨병 유병률 증가, 프리바이오틱스 제품에 대한 소비자 인식 제고, 탁월한 효능을 가진 제품들의 잇단 출시 등에서 비롯된다. 특히 변비, 과민성 대장증후군, 위식도 역류증 및 염증성 장질환 등 위장관계 질환들이 증가하면서 장 건강에 대한 관심이 높아지고 있는 추세는 프리바이오틱스 시장 성장을 가속화시킬 것으로 예상된다.The global prebiotic market is expected to continue to grow at an average annual rate of 11.6% from 2016 to '23 following the formation of $3.31 billion last year (Global Health Industry Trend, Health Industry Promotion Agency). This growth is due to an increase in the prevalence of diabetes, a rise in consumer awareness of prebiotic products, and the successive launch of products with excellent efficacy. In particular, the growing interest in gut health as gastrointestinal diseases such as constipation, irritable bowel syndrome, gastroesophageal reflux disease and inflammatory bowel disease increase are expected to accelerate the growth of the prebiotic market.
폴리감마글루탐산은 D-, L-glutamic acid가 감마 결합을 통하여 연결된 점액성의 아미노산 고분자이며 바실러스 속 균주로부터 만들어지는 천연 아미노산 고분자 소재로, 본 발명자들은 고분자량 폴리감마글루탐산 및 그 이용방법에 대한 물질특허(대한민국 특허등록 제399091), 고분자량의 폴리감마글루탐산을 생산하는 내염성 균주 바실러스 서브틸리스 청국장 균주를 사용하여 폴리감마글루탐산을 생산하는 방법에 관한 특허(대한민국 등록특허 제500796호)를 획득하였으며, 폴리감마글루탐산의 의약 용도에 대한 연구 등 지속적인 용도 개발을 수행하여 다양한 효능들을 밝혀내었다. Polygamma-glutamic acid is a mucinous amino acid polymer in which D- and L-glutamic acids are linked through gamma bonds, and is a natural amino acid polymer material made from a strain of Bacillus sp. (Korea Patent Registration No. 399091), obtained a patent on a method for producing polygammaglutamic acid using a salt-resistant strain Bacillus subtilis cheonggukjang strain that produces high molecular weight polygammaglutamic acid (Korean Patent Registration No. 500796), Through continuous use development, such as research on the medicinal use of polygamma-glutamic acid, various effects were revealed.
이에, 본 발명자들은 상기 종래 사용되는 프리바이오틱스의 문제점을 개선하고자 예의 노력한 결과, 폴리감마글루탐산 섭취 시 장내 유익균의 증진 및 장내 유해균을 억제시킬 수 있다는 것을 확인하고, 본 발명을 완성하게 되었다.Accordingly, the present inventors have made diligent efforts to improve the problems of the conventionally used prebiotics, and as a result of ingestion of polygamma-glutamic acid, it was confirmed that beneficial bacteria in the intestines and harmful bacteria in the intestines could be inhibited, and the present invention was completed.
본 발명의 목적은 섭취시 장내 유익균을 증진키시고 장내 유해균을 억제시킬 수 있는 프리바이오틱스 조성물을 제공하는데 있다.It is an object of the present invention to provide a prebiotic composition capable of promoting beneficial intestinal bacteria and inhibiting intestinal harmful bacteria upon ingestion.
상기 목적을 달성하기 위하여, 본 발명은 폴리감마글루탐산을 함유하는 프리바이오틱스 조성물을 제공한다.In order to achieve the above object, the present invention provides a prebiotic composition containing polygamma-glutamic acid.
본 발명은 또한, 폴리감마글루탐산 및 그 염을 함유하는 프리바이오틱스 조성물을 함유하는 식품, 건강기능 식품, 의약품 또는 사료를 제공한다. The present invention also provides a food, health functional food, medicine or feed containing a prebiotic composition containing polygamma-glutamic acid and a salt thereof.
본 발명에 따르면, 폴리감마글루탐산을 함유하는 프리바이오틱스 조성물은 장내 유익균을 증진키시고 장내 유해균을 억제시키는 효과가 있다.According to the present invention, a prebiotic composition containing polygamma-glutamic acid has an effect of promoting beneficial intestinal bacteria and inhibiting intestinal harmful bacteria.
도 1은 폴리감마글루탐산 경구 투여 후 시간에 따른 장기 내 폴리감마글루탐산 분포 변화를 나타낸 것이다.
도 2는 고분자량 및 저분자량 폴리감마글루탐산을 투여한 마우스 분변에서의 목(Order) 수준에서의 미생물 균총 변화를 나타낸 것이다.
도 3은 고분자량 및 저분자량 폴리감마글루탐산을 투여한 마우스 분변에서의 종(Species) 수준에서의 미생물 균총 변화를 나타낸 것이다.1 shows a change in the distribution of poly-gamma-glutamic acid in an organ according to time after oral administration of poly-gamma-glutamic acid.
Figure 2 shows the changes in the microbial flora at the level of the neck (Order) in mouse feces administered with high molecular weight and low molecular weight polygamma-glutamic acid.
Figure 3 shows the changes in the microbial flora at the species (Species) level in mouse feces administered with high molecular weight and low molecular weight poly-gamma-glutamic acid.
본 발명에서는 폴리감마글루탐산 경구 섭취 시 장내 유익균을 증진키시고 장내 유해균을 억제시킬 수 있다는 것을 동물 실험을 통하여 확인하였다.In the present invention, it was confirmed through animal experiments that polygamma-glutamic acid can promote beneficial intestinal bacteria and inhibit intestinal harmful bacteria when oral ingestion is performed.
본 발명에서는 폴리감마글루탐산의 약동학적(pharmacokinetics) 연구를 수행하여 폴리감마글루탐산 경구 섭취 시 혈액, 장기 및 뇨에서는 검출되지 않았으며 대장에서 가장 오랜시간 동안 머무르고 있음을 확인하였다.In the present invention, by conducting a study on the pharmacokinetics of polygamma-glutamic acid, it was confirmed that polygamma-glutamic acid was not detected in blood, organs, and urine when ingested orally, and stayed in the colon for the longest time.
따라서, 본 발명은 일 관점에서, 폴리감마글루탐산을 함유하는 프리바이오틱스 조성물에 관한 것이다.Accordingly, the present invention, in one aspect, relates to a prebiotic composition containing polygamma-glutamic acid.
본 발명에서 사용된 폴리감마글루탐산은 미생물에 의해 생산되는 것을 사용하는 것이 바람직하며, 본 발명의 일 양태에서는 바실러스 서브틸리스 청국장 균주(Bacillus substilis chungkookjang, KCTC 0697BP)가 생산하는 폴리감마글루탐산을 사용하였으며, 상기 바실러스 서브틸리스 청국장 균주는 대한민국 등록특허 제10-2001-1481호 및 국제출원 PCT/KR01/01372호에 그 분리, 동정과정, 생리학적 특성 등이 상세히 기재되어 있다.Poly-gamma-glutamic acid used in the present invention is preferably produced by microorganisms, and in one aspect of the present invention, poly-gamma-glutamic acid produced by Bacillus substilis chungkookjang (KCTC 0697BP) was used. , The Bacillus subtilis cheongkukjang strain is described in detail in Korean Patent Registration No. 10-2001-1481 and International Application PCT/KR01/01372 No., isolation, identification process, physiological characteristics, and the like.
폴리감마글루탐산은 프리바이오틱스 L 당 0.001~5%로 첨가될 수 있고, 이는 0.001% 미만으로 첨가될 경우 프리바이오틱스로서의 효능을 기대할 수 없고, 5%를 초과시에는 작용에는 차이가 없으며, 점성이 과도하게 증가되는 문제가 발생한다.Polygamma-glutamic acid can be added at 0.001 to 5% per L of prebiotics, and when it is added at less than 0.001%, efficacy as a prebiotic cannot be expected, and when it exceeds 5%, there is no difference in action and viscosity The problem of over-increasing arises.
다른 관점에서, 본 발명은 폴리감마글루탐산 및 그 염을 함유하는 프리바이오틱스 조성물을 함유하는 식품에 관한 것이다. In another aspect, the present invention relates to a food containing a prebiotic composition containing polygamma glutamic acid and a salt thereof.
또 다른 관점에서, 본 발명은 폴리감마글루탐산 및 그 염을 함유하는 프리바이오틱스 조성물을 함유하는 건강기능 식품에 관한 것이다. In another aspect, the present invention relates to a health functional food containing a prebiotic composition containing polygamma-glutamic acid and a salt thereof.
본 발명의 기능성 식품은 산화 예방을 위한 약제, 식품 및 음료 등에 다양하게 이용될 수 있다. 본 발명의 기능성 식품은, 예를 들어, 각종 식품류, 캔디, 초콜릿, 음료, 껌, 차, 비타민 복합제, 건강보조 식품류 등이 있고, 분말, 과립, 정제, 캡슐 또는 음료인 형태로 사용할 수 있다.The functional food of the present invention can be used in various ways, such as a pharmaceutical, food and beverage for preventing oxidation. The functional food of the present invention includes, for example, various foods, candy, chocolate, beverage, gum, tea, vitamin complex, health supplement, and the like, and may be used in powder, granule, tablet, capsule or beverage form.
본 발명의 상기 추출물은 장내 유익균 증식을 목적으로 식품 또는 음료에 첨가될 수 있다. 이 때, 식품 또는 음료 중의 상기 추출물의 양은 일반적으로 본 발명의 건강 기능 식품 조성물은 전체 식품 중량의 0.01 내지 50 중량%, 바람직하게는 0.1 내지 20 중량%로 가할 수 있으며, 건강 음료 조성물은 100 ㎖를 기준으로 0.02 내지 10 g, 바람직하게는 0.3 내지 1 g의 비율로 가할 수 있다. The extract of the present invention may be added to food or beverage for the purpose of growth of beneficial intestinal bacteria. At this time, the amount of the extract in food or beverage is generally 0.01 to 50% by weight of the total food weight of the health functional food composition of the present invention, preferably 0.1 to 20% by weight, and the health drink composition is 100 ml It can be added in a ratio of 0.02 to 10 g, preferably 0.3 to 1 g, based on the
본 발명의 건강 음료 조성물은 지시된 비율로 필수 성분으로서 상기 추출물을 함유하는 외에는 액체성분에는 특별한 제한점은 없으며 통상의 음료와 같이 여러 가지 향미제 또는 천연 탄수화물 등을 추가 성분으로서 함유할 수 있다. 상술한 천연 탄수화물의 예는 모노사카라이드, 예를 들어, 포도당, 과당 등의 디사카라이드, 예를 들어 말토스, 슈크로스 등의 폴리사카라이드, 예를 들어 덱스트린, 시클로덱스트린 등과 같은 통상적인 당 및 자일리톨, 소르비톨, 에리트리톨 등의 당알콜이다. 상술한 것 이외의 향미제로서 천연 향미제(타우마틴, 스테비아 추출물(예를 들어 레바우디오시드 A, 글리시르히진등) 및 합성 향미제(사카린, 아스파르탐 등)를 유리하게 사용할 수 있다. 상기 천연 탄수화물의 비율은 본 발명의 조성물 100 ㎖당 일반적으로 약 1 내지 20g, 바람직하게는 약 5 내지 12g이다.The health beverage composition of the present invention has no particular limitation on the liquid component except for containing the extract as an essential component in the indicated ratio, and may contain various flavoring agents or natural carbohydrates as additional components, as in a conventional beverage. Examples of the above-mentioned natural carbohydrates include monosaccharides, for example, disaccharides such as glucose and fructose, for example, polysaccharides such as maltose and sucrose, for example, conventional sugars such as dextrin, cyclodextrin, and the like. and sugar alcohols such as xylitol, sorbitol, and erythritol. As flavoring agents other than those described above, natural flavoring agents (taumatin, stevia extract (for example, rebaudioside A, glycyrrhizin, etc.) and synthetic flavoring agents (saccharin, aspartame, etc.) can be advantageously used. The proportion of the natural carbohydrate is generally about 1 to 20 g, preferably about 5 to 12 g per 100 ml of the composition of the present invention.
상기 외에 본 발명의 조성물은 여러가지 영양제, 비타민, 광물(전해질), 합성 풍미제 및 천연 풍미제 등의 풍미제, 착색제 및 중진제(치즈, 초콜릿 등), 펙트산 및 그의 염, 알긴산 및 그의 염, 유기산, 보호성 콜로이드 증점제, pH 조절제, 안정화제, 방부제, 글리세린, 알콜, 탄산 음료에 사용되는 탄산화제 등을 함유할 수 있다. 그밖에 본 발명의 조성물들은 천연 과일 쥬스 및 과일 쥬스 음료 및 야채 음료의 제조를 위한 과육을 함유할 수 있다. 이러한 성분은 독립적으로 또는 조합하여 사용할 수 있다. 이러한 첨가제의 비율은 그렇게 중요하진 않지만 본 발명의 조성물 100 중량부 당 0 내지 약 20 중량부의 범위에서 선택되는 것이 일반적이다.In addition to the above, the composition of the present invention includes various nutrients, vitamins, minerals (electrolytes), flavoring agents such as synthetic flavoring agents and natural flavoring agents, coloring agents and thickening agents (cheese, chocolate, etc.), pectic acid and its salts, alginic acid and salts thereof , organic acids, protective colloidal thickeners, pH adjusters, stabilizers, preservatives, glycerin, alcohols, carbonation agents used in carbonated beverages, and the like. In addition, the compositions of the present invention may contain natural fruit juice and pulp for the production of fruit juice beverages and vegetable beverages. These components may be used independently or in combination. The proportion of these additives is not so critical, but is generally selected in the range of 0 to about 20 parts by weight per 100 parts by weight of the composition of the present invention.
또 다른 관점에서, 본 발명은 폴리감마글루탐산 및 그 염을 함유하는 프리바이오틱스 조성물을 함유하는 의약품에 관한 것이다. In another aspect, the present invention relates to a pharmaceutical product containing a prebiotic composition containing polygammaglutamic acid and a salt thereof.
본 발명에 따른 의약 조성물의 투여 경로는 이들로 한정되는 것은 아니지만 구강, 정맥내, 근육내, 동맥내, 골수내, 경막내, 심장내, 경피, 피하, 복강내, 비강내, 장관, 국소, 설하 또는 직장이 포함된다. The route of administration of the pharmaceutical composition according to the present invention is not limited thereto, but oral, intravenous, intramuscular, intraarterial, intramedullary, intrathecal, intracardiac, transdermal, subcutaneous, intraperitoneal, intranasal, intestinal, topical, sublingual or rectal.
경구 및 비경구 투여가 바람직하다. 본원에 사용된 용어 "비경구"는 피하, 피내, 정맥내, 근육내, 관절내, 활액낭내, 흉골내, 경막내, 병소내 및 두개골내 주사 또는 주입 기술을 포함한다. Oral and parenteral administration is preferred. As used herein, the term "parenteral" includes subcutaneous, intradermal, intravenous, intramuscular, intraarticular, intrabursar, intrasternal, intrathecal, intralesional and intracranial injection or infusion techniques.
약제학적 조성물은 멸균 주사용 수성 또는 유성 현탁액으로서 멸균 주사용 제제의 형태일 수 있다. 이 현탁액은 적합한 분산제 또는 습윤제(예, 트윈 80) 및 현탁화제를 사용하여 본 분야에 공지된 기술에 따라 제형될 수 있다. 멸균 주사용 제제는 또한 무독성의 비경구적으로 허용되는 희석제 또는 용매중의 멸균 주사용액 또는 현탁액(예, 1,3-부탄디올중의 용액)일 수 있다. 허용적으로 사용될 수 있는 비히클 및 용매로는 만니톨, 물, 링겔 용액 및 등장성 염화나트륨 용액이 있다. 또한, 멸균 불휘발성 오일이 통상적으로 용매 또는 현탁화 매질로서 사용된다. 이러한 목적을 위해, 합성 모노 또는 디글리세라이드를 포함하여 자극성이 적은 어떠한 불휘발성 오일도 사용할 수 있다. 올레산 및 이의 글리세라이드 유도체와 같은 지방산이 약제학적으로 허용되는 천연 오일(예, 올리브유 또는 피마자유), 특히 이들의 폴리옥시에틸화된 것과 마찬가지로 주사 제제에 유용하다.The pharmaceutical composition may be in the form of a sterile injectable preparation as a sterile injectable aqueous or oleaginous suspension. This suspension may be formulated according to techniques known in the art using suitable dispersing or wetting agents (eg, Tween 80) and suspending agents. The sterile injectable preparation may also be a sterile injectable solution or suspension (eg, a solution in 1,3-butanediol) in a non-toxic parenterally acceptable diluent or solvent. Vehicles and solvents that can be used permissibly include mannitol, water, Ringel's solution and isotonic sodium chloride solution. In addition, sterile, nonvolatile oils are conventionally employed as the solvent or suspending medium. For this purpose, any non-volatile oil with less irritation may be used, including synthetic mono or diglycerides. Fatty acids such as oleic acid and its glyceride derivatives are useful in injectable formulations as are pharmaceutically acceptable natural oils (eg olive oil or castor oil), especially their polyoxyethylated ones.
본 발명의 약제학적 조성물은 이들로 한정되는 것은 아니지만 캡슐, 정제 및 수성 현탁액 및 용액을 포함하여 경구적으로 허용되는 어떠한 용량형으로도 경구 투여될 수 있다. 경구용 정제의 경우, 흔히 사용되는 담체로는 락토즈 및 옥수수 전분이 포함된다. 마그네슘 스테아레이트와 같은 윤활제가 또한 전형적으로 첨가된다. 캡슐형으로 경구 투여하는 경우 유용한 희석제로는 락토즈 및 건조된 옥수수 전분이 포함된다. 수성 현탁액이 경구 투여될 때 활성 성분은 유화제 및 현탁화제와 배합된다. 필요한 경우, 감미제 및/또는 풍미제 및/또는 착색제가 첨가될 수 있다.The pharmaceutical composition of the present invention may be orally administered in any orally acceptable dosage form including, but not limited to, capsules, tablets, and aqueous suspensions and solutions. For oral tablets, commonly used carriers include lactose and corn starch. Lubricants such as magnesium stearate are also typically added. Useful diluents for oral administration in capsule form include lactose and dried corn starch. When aqueous suspensions are administered orally, the active ingredient is combined with emulsifying and suspending agents. If desired, sweetening and/or flavoring and/or coloring agents may be added.
본 발명의 약제학적 조성물은 또한 직장 투여를 위한 좌제의 형태로 투여될 수 있다. 이들 조성물은 본 발명의 화합물을 실온에서 고형이지만 직장 온도에서는 액상인 적합한 비자극성 부형제와 혼합하여 제조할 수 있다. 이러한 물질로는 이들로 한정되는 것은 아니지만 코코아 버터, 밀랍 및 폴리에틸렌 글리콜이 포함된다.The pharmaceutical composition of the present invention may also be administered in the form of a suppository for rectal administration. These compositions can be prepared by mixing a compound of the present invention with a suitable non-irritating excipient that is solid at room temperature but liquid at rectal temperature. Such materials include, but are not limited to, cocoa butter, beeswax, and polyethylene glycol.
본 발명에 따른 약제학적 조성물의 경구 투여는 목적하는 치료가 국소 적용으로 접근이 용이한 부위 또는 기관과 관련이 있을 때 특히 유용하다. 피부에 국소적으로 적용하는 경우, 약제학적 조성물은 담체에 현탁 또는 용해된 활성 성분을 함유한 적합한 연고로 제형되어야 한다. 본 발명의 화합물을 국소 투여하기 위한 담체로는 이들로 한정되는 것은 아니지만 광유, 유동 파라핀, 백색 와셀린, 프로필렌 글리콜, 폴리옥시에틸렌, 폴리옥시프로필렌 화합물, 유화 왁스 및 물이 포함된다. 다른 방도로서, 약제학적 조성물은 담체에 현탁 또는 용해된 활성 화합물을 함유한 적합한 로션 또는 크림으로 제형될 수 있다. 적합한 담체로는 이들로 한정되는 것은 아니지만 광유, 솔비탄 모노스테아레이트, 폴리솔베이트 60, 세틸 에스테르 왁스, 세테아릴 알코올, 2-옥틸도데카놀, 벤질 알코올 및 물이 포함된다. 본 발명의 약제학적 조성물은 또한 직장 좌제에 의해 또한 적합한 관장제로 하부 장관으로 국소 적용할 수 있다. 국소 적용된 경피 패치가 또한 본 발명에 포함된다.Oral administration of a pharmaceutical composition according to the present invention is particularly useful when the desired treatment involves a site or organ easily accessible by topical application. For topical application to the skin, the pharmaceutical composition should be formulated in a suitable ointment containing the active ingredient suspended or dissolved in a carrier. Carriers for topical administration of the compounds of the present invention include, but are not limited to, mineral oil, liquid paraffin, white petrolatum, propylene glycol, polyoxyethylene, polyoxypropylene compounds, emulsifying waxes and water. Alternatively, the pharmaceutical composition may be formulated as a suitable lotion or cream containing the active compound suspended or dissolved in a carrier. Suitable carriers include, but are not limited to, mineral oil, sorbitan monostearate, polysorbate 60, cetyl ester wax, cetearyl alcohol, 2-octyldodecanol, benzyl alcohol and water. The pharmaceutical compositions of the present invention may also be topically applied to the lower intestinal tract by rectal suppository and with a suitable enema. Topically applied transdermal patches are also included in the present invention.
본 발명의 약제학적 조성물은 비내 에어로졸 또는 흡입에 의해 투여할 수 있다. 이러한 조성물은 약제의 분야에 잘 알려진 기술에 따라 제조하며 벤질 알코올 또는 다른 적합한 보존제, 생체이용율을 증강시키기 위한 흡수 촉진제, 플루오로카본 및/또는 기타 본 분야에 알려진 가용화제 또는 분산제를 사용하여 염수중의 용액으로서 제조할 수 있다. The pharmaceutical composition of the present invention may be administered by nasal aerosol or inhalation. Such compositions are prepared according to techniques well known in the art of pharmaceuticals and are prepared in saline with benzyl alcohol or other suitable preservatives, absorption enhancers to enhance bioavailability, fluorocarbons and/or other solubilizing or dispersing agents known in the art. It can be prepared as a solution.
특정 환자에 대한 특정 유효량은 사용된 특정 화합물의 활성, 연령, 체중, 일반적인 건강, 성별, 규정식, 투여시간, 투여경로, 배출율, 약물 배합 및 예방 또는 치료될 특정 질환의 중증을 포함한 여러 요인에 따라 변할 수 있음은 이해될 것이다. 본 발명에 따른 의약 조성물은 환제, 당의정, 캡슐, 액제, 겔, 시럽, 슬러리, 현탁제로 제형될 수 있다. The specific effective amount for a particular patient will depend on several factors, including the activity of the particular compound used, age, weight, general health, sex, diet, time of administration, route of administration, excretion rate, drug formulation, and severity of the particular disease to be prevented or treated. It will be understood that this may vary accordingly. The pharmaceutical composition according to the present invention may be formulated as pills, dragees, capsules, solutions, gels, syrups, slurries, and suspensions.
본 발명에 따른 의약 조성물을 어류의 피하세포에 투입할 경우 새낭 또는 소화관에 투여할 수 있다. 주사는 근육조직내의 근육세포 또는 다른 세포에 주사할 수 있으며 복강내의 내장세포에 주사할 수 있다.When the pharmaceutical composition according to the present invention is injected into the subcutaneous cells of a fish, it may be administered to the bird sac or the digestive tract. The injection can be injected into muscle cells or other cells in the muscle tissue, and can be injected into the intestinal cells in the abdominal cavity.
바람직한 양태로서, 구강내 투여를 위한 의약 조성물은 고체상의 부형제와 함께 활성 성분을 혼합함으로써 제조할 수 있으며 정제 또는 당의정 형태로 제조하기 위해 과립형태로 제조할 수 있다. 적합한 부형제로는 락토스, 수크로스, 만니톨 및 소비톨과 같은 슈가 형태 또는 옥수수, 밀가루, 쌀, 감자 또는 다른 식물로부터 전분, 메틸 셀룰로스, 하이드로시프로필메틸-셀룰로스 또는 나트륨 카복시메틸세룰로스와 같은 세룰로스, 아라빅 검, 타가칸쓰 검을 포함하는 검류와 같은 카보하이드레이트 또는 젤라틴, 콜라겐과 같은 단백질 필러를 사용할 수 있다. 필요한 경우에는, 교차결합된 폴리비닐피롤리돈, 아가 및 알긴산 또는 나트륨 알긴산과 같은 각각의 염 형태의 붕해제 또는 용해제를 첨가할 수 있다.In a preferred embodiment, the pharmaceutical composition for oral administration may be prepared by mixing the active ingredient with a solid excipient, and may be prepared in the form of granules for preparation in the form of tablets or dragees. Suitable excipients include, but are not limited to, sugar forms such as lactose, sucrose, mannitol and sorbitol, or starch from corn, wheat flour, rice, potatoes or other plants, cellulose such as methyl cellulose, hydroxypropylmethyl-cellulose or sodium carboxymethylcellulose Carbohydrates such as gums, including gum arabic, gum tagacanth, or protein fillers such as gelatin and collagen can be used. If necessary, disintegrants or solubilizers in the form of cross-linked polyvinylpyrrolidone, agar and their respective salts such as alginic acid or sodium alginic acid may be added.
바람직한 양태로서, 비경구적 투여의 경우 본 발명의 의약 조성물은 수용성 용액으로 제조할 수 있다. 바람직하게는, 한스 용액 (Hank's solution), 링거 용액 (Ringer's solution) 또는 물리적으로 완충된 염수와 같은 물리적으로 적절한 완충용액을 사용할 수 있다. 수용성 주입 (injection) 현탁액은 소디움 카복시메틸 셀루로스, 솔비톨 또는 덱스트란과 같이 현탁액의 점도를 증가시킬 수 있는 기질을 첨가할 수 있다. 덧붙여서, 활성 성분의 현탁액은 적합한 유질의 주입 현탁액 (oily injection suspensions)으로 제조될 수 있다. 적합한 친지성 용매 또는 담체는 참기름과 같은 지방산 또는 에틸 올레이트, 트리글리세라이드 또는 리포솜과 같은 합성 지방산 에스테르를 포함한다. 복수양이온성 비지질 아미노 폴리머(polycationic amino polymers)도 운반체로서 사용될 수 있다. 임의로, 현탁액은 화합물의 용해도를 증가시키고 고농도의 용액을 제조하기 위해 적합한 안정화제 또는 약제를 사용할 수 있다.In a preferred embodiment, for parenteral administration, the pharmaceutical composition of the present invention can be prepared as an aqueous solution. Preferably, a physically suitable buffer solution such as Hank's solution, Ringer's solution or physically buffered saline may be used. Aqueous injection suspensions may contain a substrate capable of increasing the viscosity of the suspension, such as sodium carboxymethyl cellulose, sorbitol or dextran. In addition, suspensions of the active ingredient may be prepared as suitable oily injection suspensions. Suitable lipophilic solvents or carriers include fatty acids such as sesame oil or synthetic fatty acid esters such as ethyl oleate, triglycerides or liposomes. Polycationic amino polymers may also be used as carriers. Optionally, the suspension may use suitable stabilizers or agents to increase the solubility of the compound and to prepare solutions of high concentration.
또 다른 관점에서, 본 발명은 폴리감마글루탐산 및 그 염을 함유하는 프리바이오틱스 조성물을 함유하는 사료에 관한 것이다. In another aspect, the present invention relates to a feed containing a prebiotic composition containing polygammaglutamic acid and a salt thereof.
이하 본 발명을 실시예에 의하여 더욱 상세히 설명하고자 한다. 이들 실시예는 단지 본 발명을 보다 구체적으로 설명하기 위한 것으로, 본 발명의 범위가 이들 실시예에 국한되지 않는다는 것은 당업계에서 통상의 지식을 가진 자에게 있어서 자명할 것이다. Hereinafter, the present invention will be described in more detail by way of Examples. These examples are merely for illustrating the present invention in more detail, and it will be apparent to those of ordinary skill in the art that the scope of the present invention is not limited to these examples.
실시예 1: 폴리감마글루탐산 또는 그 염의 제조Example 1: Preparation of polygamma-glutamic acid or a salt thereof
폴리감마글루탐산 생산용 기본배지(3%의 L-글루탐산이 첨가된 배지; glucose 3%, (NH4)2SO4 1%, KH2PO4 0.27%, Na2HPO412H2O 0.17%, NaCl 0.1%, sodium citrate 0.5%, soypeptone 0.02%, MgSO47H2O 0.7%, vitamin solution 10 ml/L, pH 6.8)를 멸균, 준비하여 5 L Jar fermentor(working vol. 3 L)에 바실러스 서브틸리스 청국장 균주(Bacillus subtilis var chungkookjang, KCTC 0697BP)의 종균 배양액(LB medium)을 4% 접종하여 발효 진행하였다. 교반속도는 500 rpm, 공기주입속도는 1.0 vvm으로 하여 37℃에서 48시간 동안 발효 종료 후 필터프레스(규조토 celite 1%)를 사용하여 균체를 제거하여 폴리감마글루탐산 함유 시료액으로 사용하였다.Basic medium for polygamma-glutamic acid production (3% L-glutamic acid added; glucose 3%, (NH 4 ) 2 SO 4 1%, KH 2 PO 4 0.27%, Na 2 HPO 4 12H 2 O 0.17%, NaCl 0.1%, sodium citrate 0.5%, soypeptone 0.02%, MgSO 4 7H 2 O 0.7%,
폴리감마글루탐산 함유 시료액에 염산용액을 이용 pH 2.0으로 조정 후 10℃에서 15시간 동안 정치시켜 폴리감마글루탐산 침전물을 수득하였다. 이것을 충분한 양의 냉각 증류수(10℃ 이하)로 세척한 후(pH 3.5 이상), 누체여과기를 이용하여 폴리감마글루탐산 침전물을 수득 후 동결건조하였다.A poly-gamma-glutamic acid-containing sample solution was adjusted to pH 2.0 using a hydrochloric acid solution, and then left at 10°C for 15 hours to obtain a polygamma-glutamic acid precipitate. This was washed with a sufficient amount of cold distilled water (10° C. or less) (pH 3.5 or higher), and then a polygamma-glutamic acid precipitate was obtained using a Nutche filter and then freeze-dried.
폴리감마글루탐산 염 제조시에는 염산용액을 이용하여 침전시켜 얻은 폴리감마글루탐산 침전물에 식품첨가물 수산화칼륨을 첨가하여 중성의 pH로 용해시켜 얻은 폴리감마글루탐산 칼륨염 용액을 동결건조하여 폴리감마글루탐산 칼륨염 분말을 제조하였다.In the preparation of polygamma-glutamic acid salt, the polygammaglutamic acid potassium salt solution obtained by adding potassium hydroxide as a food additive to the polygammaglutamic acid precipitate obtained by precipitation with hydrochloric acid solution and dissolving it at a neutral pH is freeze-dried to powder polygammaglutamic acid potassium salt was prepared.
실시예 2: 폴리감마글루탐산의 약동학적 연구Example 2: Pharmacokinetic study of polygammaglutamic acid
본 발명에서 Gd(Gadolinum, 원자량 157.25)이 결합된 폴리감마글루탐산을 마우스에 경구투여 후, ICP-MS로 분석하여 경과 시간에 따른 약동학적 시험을 실시하였다. Macrocyclics사에서 구입한 Bz-DTPA와 Sigma-Aldrich사에서 구입한 염화 가돌리늄을 혼합하여 30분간 반응시킨 후 투석하여 건조하였다. 폴리감마글루탐산과 건조된 Bz-DTPA-Gd를 혼합하여 폴리감마글루탐산-Bz-DTPA-Gd 합성한 후 0.22㎛인 멤브레인 필터로 필터 후 투석하여 건조하였다. 폴리감마글루탐산-Bz-DTPA-Gd를 PBS에 녹여 1% solution으로 만든 후 마우스에게 각 200 μL씩 존대를 이용하여 경구 투여하였다. 각 시험군을 2, 4 시간별로 해부하여 소장, 대장, 혈액을 채취하여 검체로 하였으며, 혈액을 제외한 검체는 동결건조하여 무게를 측정하였다. 각 시료는 ICP-MS를 이용하여 체내 분포된 Gd의 함량을 측정한 후 Gd에 결합된 폴리감마글루탐산으로 변환시켜 시간에 따른 장기별 폴리감마글루탐산 함량을 계산하였다. 분석한 결과 혈액, 장기 (폐, 간, 비장, 신장) 및 뇨에서 검출되지 않았으며, 소장에서는 1.2시간째 최고농도에 도달한 후 8시간째에 최고농도의 1% 이내로 시험물질이 감소하고, 대장에서는 4시간째에 최고농도에 도달한 후 18시간째에 최고농도의 1%이내로 시험물질이 감소하는 것을 확인하였다(도 1). 폴리감마글루탐산 경구 섭취 시 혈액과 소장/대장을 제외한 장기 및 뇨에서는 검출되지 않았으며, 대장에서 가장 오랜시간 동안 머무르고 있음을 확인하였다.In the present invention, Gd (Gadolinum, atomic weight 157.25) bound polygamma-glutamic acid was orally administered to mice, and then analyzed by ICP-MS to conduct pharmacokinetic tests according to elapsed time. Bz-DTPA purchased from Macrocyclics and gadolinium chloride purchased from Sigma-Aldrich were mixed and reacted for 30 minutes, followed by dialysis and drying. Poly-gamma-glutamic acid and dried Bz-DTPA-Gd were mixed to synthesize polygamma-glutamic acid-Bz-DTPA-Gd, filtered through a 0.22 μm membrane filter, and then dialyzed to dryness. After dissolving polygamma-glutamic acid-Bz-DTPA-Gd in PBS to make a 1% solution, 200 μL each was orally administered to mice using a zona pod. Each test group was dissected for 2 and 4 hours, and small intestine, large intestine, and blood were collected and used as specimens. Samples except blood were freeze-dried and weighed. After measuring the content of Gd distributed in the body using ICP-MS, each sample was converted into polygamma-glutamic acid bound to Gd to calculate the polygamma-glutamic acid content for each organ according to time. As a result of the analysis, it was not detected in blood, organs (lung, liver, spleen, kidney) and urine. In the small intestine, after reaching the highest concentration at 1.2 hours, the test substance decreased to within 1% of the maximum concentration at 8 hours. In the large intestine, after reaching the maximum concentration at 4 hours, it was confirmed that the test substance decreased to within 1% of the maximum concentration at 18 hours (FIG. 1). When polygamma-glutamic acid was orally ingested, it was not detected in the blood, organs and urine except for the small intestine/colon, and it was confirmed that it stayed in the large intestine for the longest time.
실시예 3: 폴리감마글루탐산의 프리바이오틱스 효능 검증Example 3: Verification of prebiotic efficacy of polygamma-glutamic acid
본 발명에서 실험동물은 (주)중앙동물로부터 이유된 5주령의 C57BL/6 암컷 쥐 9마리를 사용했다. 실험실 환경조건은 온도 22 ㅁ 2 ℃, 상대 습도 65 ㅁ 5 % 와 낮과 밤 주기는 12시간(오후 9시에 불이 켜짐)으로 하였으며, 각각 개별적인 금속 케이지에서 사육했다. 새로운 환경에 적응이 끝난 후, 실험동물은 대조군(PBS 투여) 3마리와 고분자량 폴리감마글루탐산 섭취군 3마리, 저분자량 폴리감마글루탐산 섭취군 3마리로 무작위 실험군을 나누어 고분자량 및 저분자량 폴리감마글루탐산을 400 ug/day의 용량으로 2주간 경구 투여하였다. 분변 시료는 투여전 및 투여 후 14일 후 채취하였다. In the present invention, as experimental animals, 9 5-week-old C57BL/6 female mice weaned from JoongAng Animals were used. The laboratory environment conditions were a temperature of 22 ㅁ 2 ℃, a relative humidity of 65 ㅁ 5 %, and a day and night cycle of 12 hours (lights turned on at 9 pm), and they were reared in individual metal cages. After adaptation to the new environment, the experimental animals were randomly divided into 3 control groups (administered with PBS), 3 animals in the high molecular weight polygamma-glutamic acid intake group, and 3 animals in the low molecular weight polygammaglutamic acid intake group. Glutamic acid was orally administered at a dose of 400 ug/day for 2 weeks. Fecal samples were collected before administration and 14 days after administration.
채취한 분변에서 원래의 군집 구조를 그대로 반영할 수 있는 DNA를 얻기 위해 분변 채취 후 한시간 이내에 물리적 파괴를 이용하는 FastDNA Spin Kit (MP Biomedicals, USA)를 사용하여 분변 내 미생물의 메타게노믹 DNA를 추출하였다. 추출한 DNA를 아가로스 겔상의 전기영동을 통하여 DNA의 상태를 확인한 뒤, 파이로 시퀀싱(pyro-sequencing)을 실시하여 장내 균총 분포 분석을 진행하였다. 추출한 DNA 시료는 Roche 454 GS FLX(454 Life Science, USA)를 이용하여 장관내 균총의 16S rDNA 유전자서열을 분석하였다. 얻어진 자료는 파이로시퀀싱 비주얼라이제이션 소프트웨어(pyro-sequencing visualization software)인 CLcommunityTM을 이용하여 분석하였다.Metagenomic DNA of microorganisms in feces was extracted using FastDNA Spin Kit (MP Biomedicals, USA) that uses physical destruction within one hour after fecal collection to obtain DNA that can reflect the original colony structure from the collected feces. . After confirming the state of the extracted DNA through electrophoresis on an agarose gel, pyro-sequencing was performed to analyze the distribution of intestinal flora. The extracted DNA sample was analyzed for 16S rDNA gene sequence of intestinal flora using Roche 454 GS FLX (454 Life Science, USA). The obtained data were analyzed using CLcommunity TM , a pyro-sequencing visualization software.
분석 결과 폴리감마글루탐산 섭취에 의해 문(Phylum) 수준에서는 변화를 확인할 수 없었으나 목(Order) 수준에서는 고분자량 및 저분자량 폴리감마글루탐산 섭취에 의해 락토바실라세아에(Lactobacillaceae) 균총의 증가 및 클로스트리디알레스(Clostridiales) 균총의 감소를 확인할 수 있었다(도 2). 또한 종(Species) 수준에서의 결과에서는 고분자량 폴리감마글루탐산에 의해 Lactobacillus intestinalis 및 미동정 균주의 증가를 보였으며 저분자량 폴리감마글루탐산 섭취 후에는 Lactobacillus animalis의 증가가 나타났다(도 3). As a result of the analysis, no change was confirmed at the Phylum level due to the ingestion of polygamma-glutamic acid, but at the order level, the increase in Lactobacillaceae colonies and the growth of Lactobacillaceae by ingestion of high molecular weight and low molecular weight polygammaglutamic acid It was confirmed that the reduction of the tridiales (Clostridiales) colonies ( FIG. 2 ). In addition, the results at the species level showed an increase in Lactobacillus intestinalis and unidentified strains by high molecular weight polygamma-glutamic acid, and an increase in Lactobacillus animalis after ingestion of low molecular weight polygammaglutamic acid (FIG. 3).
이상으로, 본 발명 내용의 특정한 부분을 상세히 기술하였는바, 당업계의 통상의 지식을 가진 자에게 있어서, 이러한 구체적 기술은 단지 바람직한 실시양태일 뿐이며, 이에 의해 본 발명의 범위가 제한되는 것이 아닌 점은 명백할 것이다. 따라서 본 발명의 실질적인 범위는 첨부된 청구항들과 그것들의 등가물에 의하여 정의된다고 할 것이다. As described above, specific parts of the present invention have been described in detail, and for those of ordinary skill in the art, these specific descriptions are only preferred embodiments, and the scope of the present invention is not limited thereby. It will be obvious. Accordingly, the substantial scope of the present invention will be defined by the appended claims and their equivalents.
Claims (7)
A prebiotic composition comprising polygamma-glutamic acid and a salt thereof.
The composition according to claim 1, wherein the salt is a potassium salt.
The prebiotic composition according to claim 1, wherein the Lactobacillaceae flora increases and the Clostridiales population decreases.
A food containing the prebiotic composition of claim 1.
A health functional food containing the prebiotic composition of claim 1.
A pharmaceutical comprising the prebiotic composition of claim 1 as an active ingredient.
A feed containing the prebiotic composition of claim 1.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020160146854A KR102440573B1 (en) | 2016-11-04 | 2016-11-04 | Composition for Prebiotics Containing Poly-Gamma-Glutamate |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020160146854A KR102440573B1 (en) | 2016-11-04 | 2016-11-04 | Composition for Prebiotics Containing Poly-Gamma-Glutamate |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20180050093A KR20180050093A (en) | 2018-05-14 |
| KR102440573B1 true KR102440573B1 (en) | 2022-09-06 |
Family
ID=62188080
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020160146854A KR102440573B1 (en) | 2016-11-04 | 2016-11-04 | Composition for Prebiotics Containing Poly-Gamma-Glutamate |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR102440573B1 (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102116686B1 (en) | 2020-01-02 | 2020-05-29 | 주식회사 쎌바이오텍 | Composition for promoting the growth of lactic acid bacteria comprising growth factors |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101000364B1 (en) | 2010-04-26 | 2010-12-13 | 고려대학교 산학협력단 | Double-coating methods for enhancing viability |
| CN101999525A (en) | 2010-11-02 | 2011-04-06 | 河北科技大学 | Composite probiotics feed additive |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100645089B1 (en) * | 2004-07-08 | 2006-11-10 | 주식회사 바이오리더스 | Food Preservatives Comprising Culture broth of Lactic Acid Bacteria and Poly-?-glutamic Acid |
-
2016
- 2016-11-04 KR KR1020160146854A patent/KR102440573B1/en active IP Right Grant
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101000364B1 (en) | 2010-04-26 | 2010-12-13 | 고려대학교 산학협력단 | Double-coating methods for enhancing viability |
| CN101999525A (en) | 2010-11-02 | 2011-04-06 | 河北科技大学 | Composite probiotics feed additive |
Non-Patent Citations (3)
| Title |
|---|
| INTERNATIONAL JOURNAL OF FOOD MICROBIOLOGY 제196권, 24_31쪽, 2014년 12월 05일. |
| International Journal of Food Microbiology, 196(2):24-31, 2014. |
| 해양 유래 내염성 BACILLUS가 생산하는 Γ_PGA의 생화학적 효과 및 기능성에 관한 연구 |
Also Published As
| Publication number | Publication date |
|---|---|
| KR20180050093A (en) | 2018-05-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN109789173B (en) | Nanovesicles derived from bacillus bacteria and uses thereof | |
| JP5498698B2 (en) | New uses of white jellyfish miscellaneous polysaccharides or their extracts | |
| JP6684966B2 (en) | Novel Lactobacillus sakei and composition containing the same | |
| JP2018153182A (en) | Lactobacillus plantarum tci378, and use thereof in reducing fat and improving gastrointestinal function | |
| JP5592640B2 (en) | Antistress agent containing lactic acid bacteria fermented royal jelly, method for producing the same, hypothalamus-pituitary-adrenocortical activity inhibitor, and sympathetic-adrenal medullary activity inhibitor | |
| CN109315769A (en) | It is a kind of for improving the composition and preparation method thereof of human body enteral environment | |
| CN110339216A (en) | It can prevent and treat the lactic bacteria composition of bacterial vaginitis | |
| JP2021527414A (en) | Composition for improving intestinal function containing a strain of Leuconostocaceae | |
| TW202008998A (en) | An active substance oflactobacillus plantarum gkm3, a composition comprising thereof and its use for promoting longevity | |
| KR101614574B1 (en) | Composition of Diabetes-Improving Effective Constituents by Fermentation Products of the Trifoliate Orange | |
| JP7379152B2 (en) | Composition for inhibiting muscle fibrosis | |
| JP4484014B2 (en) | Hyaluronidase inhibition, antiallergic activity and immunostimulatory substances | |
| TW202008996A (en) | An active substance of Bifidobacterium lactis GKK2, a composition comprising thereof and its use for promoting longevity | |
| KR102440573B1 (en) | Composition for Prebiotics Containing Poly-Gamma-Glutamate | |
| JP2012224551A (en) | Composition for sustentation of bifidobacterium or lactobacillus | |
| JP2018070568A (en) | Nonalcoholic fatty liver disease treating or preventing agent and food for preventing nonalcoholic fatty liver disease | |
| JP6061842B2 (en) | QOL improvement or persistence agent | |
| JP5403320B2 (en) | Degreasing inhibitor, β-hexosaminidase release inhibitor, antiallergic agent and anti-inflammatory agent obtained from natural extract | |
| JP2018154612A (en) | Food composition for reducing f/b ratio, f/b ratio reducing agent, food composition for increasing akkermansia muciniphila bacterium occupancy, and akkermansia muciniphila bacterium occupancy increasing agent | |
| JP5311364B2 (en) | Anti-inflammatory composition | |
| BR112014032472B1 (en) | PROCESS TO OBTAIN A COMPOSITION UNDERSTANDING BETA-GLICAN, CHITIN AND CHITOSAN, AND RESULTING COMPOSITION OF THE SAME | |
| JP7398714B2 (en) | Akkermansia muciniphila proliferation-promoting composition applicable to medical and beauty treatments, as well as pharmaceuticals, food and beverages, and feed containing the same | |
| US20240024389A1 (en) | Lactobacillus plantarum pdg8 and use in treating cardiovascular diseases | |
| CN116262125B (en) | Lactobacillus casei L7-13 for protecting gastric mucosa and relieving gastritis and application thereof | |
| EP4289438A1 (en) | Composition for preventing, alleviating or treating sleep disorders, containing, as active ingredient, gut microbiota or extracellular vesicles derived therefrom |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| E902 | Notification of reason for refusal | ||
| E701 | Decision to grant or registration of patent right | ||
| GRNT | Written decision to grant |